Table 6 Microbiological cure or eradication in mixed/unspecified bacteremia patients receiving C/T

Case report

 Jones et al., 2020 [27]

Case report

–

Pseudomonas: 100% (not further specified), E. coli: 100%

–

Had a clinically evaluable repeat culture demonstrating microbiologic resolution

–

100% (1/1)

Retrospective cohort studies

 Caston et al., 2017 [14]

Retrospective cohort

Overall mixed infections and sepsis/septic shock

Mixed hospital-acquired infections: Abdominal, Respiratory, Otitis and mastoiditis, Biliary,

Pseudomonas: 100% (not further specified)

MDR infection: 100%

–

30 days (after therapy with C/T)

80.0% (4/5)

 Jayakumar et al., 2018 [10]

Retrospective cohort

Mixed infections: Respiratory, Blood, Urinary, Tissue, Wound (patients could have more than one infection)

Pseudomonas: 95% (not further specified)

• Polymicrobial Pseudomonas infection: Enterobacter (10%), Acinetobacter (10%), Providencia (5%),

• Meningosepheum (5%),

• Morganella (5%),

• Candida (14%)

K

Pneumoniae: 5%

MDR infection: 86% (all patients with Pseudomonas infections)

Documented negative culture of same pathogen after a previously positive culture

–

75.0% (9/12)

 King et al., 2018 [11]

Retrospective cohort

Overall Mixed infections: primary bacteremia or pneumonia, UTI, intra-abdominal, wound tested via positive blood culture

Pseudomonas: 100% (not further specified)

MDR infection: 100%

Microbiological success required a negative culture at the end of therapy

–

80.0% (20/25)

 Xipell et al., 2018 [22]

Retrospective cohort

Overall Mixed infections: submandibular fasciitis or UTI and deep surgical-site infection

–

MDR infection: 17.39%, XDR infection: 79%, PDR infection: 4%

Defined as negative cultures for P. aeruginosa after 72 h of therapy when repeated cultures from the same source were available

–

60.0% (3/5)^a